Table 3.
Descriptive table from patients included in the study.
| Patients variables (n = 232) | Controls (n = 93) | Acute (n = 35) | Convalescent (n = 104) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unvaccinated (n = 21) | Vaccinated (n = 72) | Mild (n = 8) | Moderate (n = 2) | Severe (n = 22) | Dead (n = 3) | Mild (n = 25) | Moderate (n = 22) | Severe (n = 57) | |||
| NIV (n = 17) | IMV (n = 5) | NIV (n = 26) | IMV (n = 31) | ||||||||
| Age (years ± SD) | 34.6 ± 10.4 | 41.4 ± 13.9 | 34.5 ± 16.6 | 55.1 ± 26.7 | 59.6 ± 13.1 | 63.2 ± 11.3 | 79.6 ± 2.3 | 39.9 ± 12.9 | 61 ± 14.2 | 60.6 ± 14.1 | 58.6 ± 10.2 |
| Male N (%) | 3 (14.3) | 18 (25) | 4 (50) | 2 (100) | 15 (88.2) | 4 (80) | 2 (66.7) | 5 (20) | 11 (50) | 14 (53.8) | 22 (74.2) |
| Pneumonia N (%)a | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 17 (100) | 5 (100) | 3 (100) | 0 (0) | 19 (86.4) | 26 (100) | 31 (100) |
| Unilobar | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (22.7) | 0 (0) | 1 (3.2) |
| Multilobar | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 17 (100) | 5 (100) | 3 (100) | 0 (0) | 14 (63.6) | 26 (100) | 30 (96.8) |
| ICU admission N (%)a | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (29.4) | 5 (100) | 2 (66.7) | 0 (0) | 0 (0) | 2 (7.7) | 30 (96.8) |
| Oxygen support N (%)a | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 17 (100) | 5 (100) | 3 (100) | 0 (0) | 16 (72.7) | 26 (100) | 31 (100) |
| Nasal prongs or VMK | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 16 (72.7) | 1 (3.8) | 0 (0) |
| Non-invasive mechanical vent | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 17 (100) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 26 (96.2) | 0 (0) |
| Invasive mechanical vent | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 31 (100) |
| Vaccinated with 1st dose N (%)b | 0 (0) | 72 (100) | 2 (25) | 0 (0) | 1 (5.9) | 0 (0) | 0 (0) | 13 (52) | 1 (4.5) | 0 (0) | 0 (0) |
| Vaccinated with 2nd dose N (%)b | 0 (0) | 66 (91.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 10 (40) | 0 (0) | 0 (0) | 0 (0) |
| Vaccinated with 3rd dose N (%) | 0 (0) | 3 (4.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (8) | 0 (0) | 0 (0) | 0 (0) |
| Comorbidities N (%) | 1 (4.7) | 8 (11.1) | 0 (0) | 1 (50) | 15 (88.2) | 3 (60) | 3 (100) | 3 (12) | 11 (50) | 21 (80.8) | 21 (67.7) |
| Respiratory disorders (asthma, OSAS, COPD) | 0 (0) | 2 (2.8) | 0 (0) | 1 (50) | 6 (35.3) | 0 (0) | 0 (0) | 0 (0) | 8 (36.4) | 3 (11.5) | 3 (9.7) |
| Cardiovascular diseases (AHT, ictus, atrial fibrillation) | 1 (4.7) | 2 (2.8) | 0 (0) | 1 (50) | 7 (41.2) | 3 (60) | 3 (100) | 1 (4) | 6 (27.3) | 14 (53.8) | 15 (48.4) |
| Autoimmune disorders (DM2, psoriasis, Jorgen, other) | 0 (0) | 3 (4.2) | 0 (0) | 0 (0) | 6 (35.3) | 1 (20) | 1 (33.3) | 2 (8) | 1 (4.5) | 6 (23.1) | 6 (19.4) |
| Central nervous system disorders (dementia, epilepsy, Parkinson) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | 2 (11.8) | 0 (0) | 1 (33.3) | 0 (0) | 1 (4.5) | 0 (0) | 1 (3.2) |
| Malignant neoplasies | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (20) | 1 (33.3) | 0 (0) | 1 (4.5) | 3 (11.5) | 2 (6.4) |
| Obesity | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 7 (41.2) | 1 (20) | 0 (0) | 0 (0) | 3 (13.6) | 4 (15.3) | 7 (22.6) |
| Immunosuppressive treatment N (%) | 0 (0) | 4 (5.6) | 1 (12.5) | 0 (0) | 4 (23.5) | 0 (0) | 1 (33.3) | 1 (4) | 4 (18.2) | 3 (11.5) | 2 (6.4) |
| Oral (prednisone, NSAIDS, etc.) | 0 (0) | 1 (1.4) | 1 (12.5) | 0 (0) | 2 (11.8) | 0 (0) | 1 (33.3) | 0 (0) | 4 (18.2) | 0 (0) | 1 (3.2) |
| Inhaled | 0 (0) | 2 (2.8) | 0 (0) | 0 (0) | 2 (11.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (7,7) | 1 (3.2) |
| Topic | 0 (0) | 2 (2.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (4) | 0 (0) | 1 (3.8) | 0 (0) |
| Deaths N (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
NIV non-invasive ventilation, IMV invasive mechanical ventilation, n/a not available.
aIn the convalescent group, these variables refer to the characteristics of their acute COVID-19 episode.
bSixty-six of 72 uninfected vaccinated individuals (91.7%) with two Pfizer doses.